Akili – pharmaceutical daily

April 22, 2020 Off

Akili Announces ENDEAVORTM Digital Attention Treatment is Now Available for Children with Attention Deficit Hyperactivity Disorder (ADHD) under FDA’s COVID-19 Enforcement Discretion Guidance

BOSTON–(BUSINESS WIRE)–#ADHD—Akili today announced that ENDEAVORTM (AKL-T01) is now available for use by children with attention deficit hyperactivity disorder (ADHD)…

February 25, 2020 Off

Akili Announces Publication of AKL-T01 ADHD Pivotal Study Results in the Lancet Digital Health

By BusinessWire

First publication of complete results shows improvement across both objective measures of attention and parent and clinician ratings of ADHD…

April 6, 2017 Off

PureTech’s Akili pilot study shows improved cognitive control in children with sensory processing dysfunction and attentional deficits

By Dino Mustafić

PureTech Health’s subsidiary Akili announced results from a project EVO pilot study demonstrating improved cognitive control in children with sensory processing dysfunction and attentional deficits.